DNA
Ginkgo Bioworks Holdings, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
7.47
▲ 0.51 (7.33%)
MARKET · —
Price
Open
7.00
Prev close
6.96
Day high
7.42
Day low
6.82
Volume
1.33M
Market cap
$498.32M
P/E (TTM)
—
52W range
5.37 – 17.58
Trailing performance
Returnvs SPY
1W
+8.98%
+10.4%
1M
-6.68%
-10.4%
3M
-8.42%
-11.5%
6M
-19.74%
-30.8%
YTD
-10.95%
-23.2%
1Y
-36.15%
-56.1%
3Y
-88.65%
-162.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$498.32M
Enterprise value$600.27M
Revenue (TTM)$132.42M
Gross profit$90.10M
EBITDA$-261.62M
Net income$-309.64M
EPS (TTM)$-5.33
Free cash flow$-72.40M
Total cash$302.16M
Total debt$404.11M
Book value / share$6.60
Shares outstanding55.38M
Float49.87M
Short % of float9.91%
Dividend yield—
Beta (5Y)1.79
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.55
PEG ratio—
Price / sales—
Price / book1.12
EV / revenue4.53
EV / EBITDA-2.29
Gross margin68.04%
Operating margin-284.99%
Profit margin-219.61%
Return on equity-59.94%
Return on assets-16.72%
Debt / equity96.15
Current ratio4.57
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $170.16M | $227.04M | $251.46M | $477.71M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$312.76M | -$547.03M | -$892.87M | -$2.10B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$312.76M | -$547.03M | -$892.87M | -$2.10B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.70 | -0.73 | -4.7% |
| Mar 2026 | -1.34 | -1.39 | -3.7% |
| Dec 2025 | -1.11 | -0.77 | +30.5% |
| Sep 2025 | -1.24 | -1.45 | -16.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.58 | 1 | $20.85M | -46.3% |
| Next quarter | — | — | $22.10M | -33.8% |
| Current year | -3.20 | 1 | $82.55M | -51.5% |
| Next year | -2.90 | 1 | $87.10M | +5.5% |
Analyst targets & ownership
Mean target$7.00
High target$9.00
Low target$5.00
Implied upside-6.29%
Analyst count2
ConsensusUNDERPERFORM
Strong buy / Buy0 / 0
Hold1
Sell / Strong sell1 / 1
Held by insiders4.43%
Held by institutions73.54%
Institutions holding253
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+574.76K
Net buying
Buy transactions
10
1.12M shares
Sell transactions
10
544.04K shares
Net transactions
+20
Buys less sells
Sell : buy shares
0.5 : 1
Mixed
Insider-held shares
2.99M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 17, 26 | COEN STEVEN P. Chief Financial Officer |
SELL | 752 | $5.94K | Direct |
| Jul 16, 26 | COEN STEVEN P. Chief Financial Officer |
— | 1.49K | — | Direct |
| May 22, 26 | COEN STEVEN P. Chief Financial Officer |
SELL | 307 | $2.56K | Direct |
| May 21, 26 | COEN STEVEN P. Chief Financial Officer |
— | 743 | — | Direct |
| Apr 17, 26 | COEN STEVEN P. Chief Financial Officer |
SELL | 324 | $2.58K | Direct |
| Apr 16, 26 | COEN STEVEN P. Chief Financial Officer |
— | 743 | — | Direct |
| Apr 13, 26 | COEN STEVEN P. Chief Financial Officer |
SELL | 33.17K | $212.76K | Direct |
| Apr 10, 26 | CANTON BARTHOLOMEW Beneficial Owner of more than 10% of a Class of Security |
SELL | 124.73K | $802.49K | Indirect |
| Apr 10, 26 | SHETTY RESHMA PADMINI President |
SELL | 124.73K | $802.49K | Direct |
| Apr 10, 26 | COEN STEVEN P. Chief Financial Officer |
— | 73.92K | — | Direct |
| Apr 9, 26 | CANTON BARTHOLOMEW Beneficial Owner of more than 10% of a Class of Security |
SELL | 26.27K | $175.07K | Direct |
| Apr 9, 26 | KELLY JASON R Chief Executive Officer |
SELL | 206.78K | $1.37M | Direct |
| Apr 9, 26 | SHETTY RESHMA PADMINI President |
SELL | 26.27K | $175.07K | Indirect |
| Apr 9, 26 | SHETTY RESHMA PADMINI President |
— | 251.79K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CANTON BARTHOLOMEW |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
COEN STEVEN P. |
Chief Financial Officer | 51.44K | Sale |
DMYTRUK MARK E |
Chief Financial Officer | 46.23K | Sale |
HANNAN KATHY HOPINKAH |
Director | 15.00K | Conversion of Exercise of derivative security |
HENRY CHRISTIAN O |
Director | 24.31K | Sale |
KELLY JASON R |
Chief Executive Officer | 316.48K | Sale |
KOSURI SRI |
Director | 24.07K | Conversion of Exercise of derivative security |
SANKAR SHYAM |
Director | 72.37K | Conversion of Exercise of derivative security |
SHETTY RESHMA PADMINI |
President | 436.42K | Sale |
SLOAN HARRY EVANS |
Director | 271.42K | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
7.19
+3.87% from price
SMA 20
7.75
-4.53% from price
SMA 50
8.45
-12.43% from price
SMA 100
8.30
-9.95% from price
SMA 200
8.42
-12.15% from price
EMA 12
7.40
+0.89% from price
EMA 26
7.79
-4.08% from price
EMA 50
8.10
-7.77% from price
RSI (14)
46.1
Neutral
MACD (12,26,9)
-0.38
Hist -0.03
ATR (14)
0.62
8.32% of price
Realised vol 30D
92.4%
Annualised
Bollinger upper
9.31
20, 2σ
Bollinger lower
6.20
20, 2σ
50 / 200 cross
Golden
8.45 vs 8.42
Trend bias
Below 200
-12.15%
Risk profile
Beta vs SPY
3.09
More volatile than market
Correlation to SPY
0.43
Loosely linked
Realised vol 30D
92.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-66.0%
Peak to trough
Max drawdown 5Y
-99.1%
Peak to trough
ATR 14
0.62
8.32% of price
Beta (reported)
1.79
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.17
Call-heavy session
Put / call open interest
0.29
Positioning, not flow
Max pain
7.00
-5.4% from spot
ATM implied vol
89.1%
Nearest strike to spot
Skew (10% OTM)
-1.0%
Calls bid over puts
Call volume
937
Contracts, this expiry
Put volume
163
Contracts, this expiry
Heaviest call OI
7.00
1.45K contracts
Heaviest put OI
7.00
1.00K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
24/7 Wall St. · 11d ago
Ginkgo Bioworks Q2 Earnings Call Highlights
MarketBeat · 15d ago
Ginkgo Bioworks Holdings, Inc. Q2 2026 Earnings Call Summary
Moby · 16d ago
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
PR Newswire · 88d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.